Piao Zong-Zhu, Lee Mi-Kyung, Lee Beom-Jin
National Research Laboratory for Bioavailability Control, College of Pharmacy, Kangwon National University, Chuncheon 200-701, Republic of Korea.
Int J Pharm. 2008 Feb 28;350(1-2):205-11. doi: 10.1016/j.ijpharm.2007.08.044. Epub 2007 Aug 31.
A colonic-release delivery system containing naproxen inclusion complex with 2-hydroxypropyl-beta-cyclodextrin (2-HPbetaCD) was originally proposed. The core tablets consisting of the naproxen inclusion complex and disintegrants (Ac-Di-Sol), Primojel), Avicel) or Polyplasdone) were formed by direct compression, and then coated with the polymers, either pH-dependent Eudragit S100 and/or pH-independent Eudragit RS100 with plasticizers like dibutyl sebacate (DBS) and aluminum tristearate (AT). The in vitro release characteristics were evaluated in simulated gastric fluid for 2h and then subsequently in simulated intestinal fluid for 12h. The potential histological changes were also evaluated after direct dosing of suspensions of naproxen alone and powdered mixtures of inclusion complex-loaded tablet into rat intestinal segments. No distinct colonic release was observed when disintegrants were excluded in the single-layered coated tablets regardless of coated structures, giving a zero-order fashion over 12h. The coated tablet with double-layered structures of Eudragit S100 and Eudragit RS100 was not also applicable. In contrast, colonic release was achieved when the core tablet containing inclusion complex and disintegrant was coated with only Eudragit S100 in a single-layered structure. The colonic-release tablet was resistant in gastric fluid for 2h and for 2-4h in intestinal fluid, followed by rapid release of the drug after a total of 4-6h of lag time depending on the type of disintegrants. The lag time was advanced in case of DBS while delayed in case of AT. On histological examination, the inclusion complex-loaded suspension caused less intestinal tissue damage than naproxen alone. Based on these findings, the colonic-release tablet with enteric coatings which contains inclusion complex and disintegrants could be useful to deliver drugs like naproxen to the lower small intestine and upper colon with increased dissolution and reduced intestinal tissue damage.
最初提出了一种含有萘普生与2-羟丙基-β-环糊精(2-HPβCD)包合物的结肠释放给药系统。由萘普生包合物和崩解剂(Ac-Di-Sol、Primojel、Avicel或Polyplasdone)组成的核心片剂通过直接压片形成,然后用聚合物包衣,这些聚合物包括pH依赖性的Eudragit S100和/或pH非依赖性的Eudragit RS100,并添加了诸如癸二酸二丁酯(DBS)和硬脂酸铝(AT)等增塑剂。在模拟胃液中评估2小时的体外释放特性,随后在模拟肠液中评估12小时。在将萘普生单独的混悬液和载有包合物片剂的粉末混合物直接给药到大鼠肠段后,还评估了潜在的组织学变化。当单层包衣片剂中不包含崩解剂时,无论包衣结构如何,均未观察到明显的结肠释放,在12小时内呈零级释放方式。具有Eudragit S100和Eudragit RS100双层结构的包衣片剂也不适用。相比之下,当含有包合物和崩解剂的核心片剂用单层结构的Eudragit S100包衣时,可实现结肠释放。结肠释放片剂在胃液中耐受2小时,在肠液中耐受2-4小时,根据崩解剂的类型,在总共4-6小时的滞后时间后药物迅速释放。在使用DBS的情况下滞后时间提前,而在使用AT的情况下滞后时间延迟。组织学检查显示,载有包合物的混悬液对肠组织的损伤小于单独使用萘普生。基于这些发现,含有包合物和崩解剂的肠溶包衣结肠释放片剂可能有助于将萘普生等药物递送至小肠下部和结肠上部,提高药物溶出度并减少肠组织损伤。